PHARMACOKINETICS AND SAFETY OF A SINGLE DOSE OF ELEBSIRAN ( VIR-2218, SIRNA) SUBCUTANEOUSLY ADMINISTERED IN ADULT PARTICIPANTS WITH MODERATE RENAL IMPAIRMENT

被引：0
|
作者：
Wang, Li [1 ]
El-zailik, Asma [1 ]
Boundy, Keith [1 ]
Mao, Shenghua [1 ]
Aryal, Madhukar [1 ]
Gupta, Sneha [1 ]
Reyes, Maribel [1 ]
机构：
[1] Vir Biotechnol Inc, San Francisco, CA USA
来源：
HEPATOLOGY | 2024年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
376
引用
收藏
页码：S268 / S269
页数：2
相关论文
共 50 条
  • [41] SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF A SINGLE ORALLY ADMINISTERED DOSE OF ENPATORAN IN A PHASE I STUDY OF HEALTHY JAPANESE AND CAUCASIAN PARTICIPANTS
    Gopalakrishnan, S.
    Krebs-Brown, A.
    Nogueira Filho, M.
    Kuroki, Y.
    Bachmann, A.
    Becker, A.
    Schippers, F.
    Fluck, M.
    Yalkinoglu, O.
    Klopp-Schulze, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 663 - 664
  • [42] Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment
    Magda S. C. Fontes
    Jasper Dingemanse
    Atef Halabi
    Monika Tomaszewska-Kiecana
    Patricia N. Sidharta
    Scientific Reports, 12
  • [43] Pharmacokinetics, safety and tolerability of a single oral dose of maraviroc in HIV-negative subjects with mild and moderate hepatic impairment
    Abel, Samantha
    Davis, John D.
    Ridgway, Caroline E.
    Hamlin, Julia C.
    Vourvahis, Manoli
    ANTIVIRAL THERAPY, 2009, 14 (06) : 831 - 837
  • [44] Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment
    Fontes, Magda S. C.
    Dingemanse, Jasper
    Halabi, Atef
    Tomaszewska-Kiecana, Monika
    Sidharta, Patricia N.
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [45] PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment
    Hoshide, S
    Takahashi, Y
    Ishikawa, T
    Kubo, J
    Tsuchimoto, M
    Komoriya, K
    Ohno, I
    Hosoya, T
    NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2004, 23 (8-9): : 1117 - 1118
  • [46] PHARMACOKINETICS (PK) AND SAFETY OF GLASDEGIB IN PARTICIPANTS WITH MODERATE AND SEVERE HEPATIC IMPAIRMENT: A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL-GROUP STUDY.
    Shaik, M.
    Masters, J.
    LaBadie, R.
    Salageanu, J.
    Li, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S91 - S92
  • [47] PHARMACOKINETICS AND SAFETY OF SINGLE-DOSE BEPIROVERSIN IN ADULTS WITH MODERATE HEPATIC IMPAIRMENT AND HEALTHY MATCHED CONTROLS (B-ASSURED)
    Han, K.
    Noormohamed, N.
    Lukic, T.
    Marbury, T.
    Lawitz, E.
    Prescott, H.
    Magee, M.
    Nader, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S17 - S17
  • [48] SINGLE-DOSE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF THE DUAL ENDOTHELIN RECEPTOR ANTAGONIST APROCITENTAN IN SUBJECTS WITH MODERATE HEPATIC IMPAIRMENT.
    Fontes, M.
    Halabi, A.
    Tomaszewska-Kiecana, M.
    Dinge-Manse, J.
    Sidharta, P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S47 - S48
  • [49] Single-Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End-Stage Renal Disease Requiring Hemodialysis
    Zomorodi, Katie
    Chen, Dan
    Lee, Lawrence
    Lasseter, Kenneth
    Marbury, Thomas
    JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 59 (08): : 1120 - 1129
  • [50] Single-Dose Pharmacokinetics and Safety of the Oral Galectin-3 Inhibitor, Selvigaltin (GB1211), in Participants with Hepatic Impairment
    Aslanis, Vassilios
    Gray, Michael
    Slack, Robert J.
    Zetterberg, Fredrik R.
    Tonev, Dimitar
    Phung, De
    Smith, Becky
    Jacoby, Brian
    Schambye, Hans
    Krastev, Zahari
    Ungell, Anna-Lena
    Lindmark, Bertil
    CLINICAL DRUG INVESTIGATION, 2024, 44 (10) : 773 - 787
12345